Skip to main content
. Author manuscript; available in PMC: 2021 Mar 29.
Published in final edited form as: Cancer Discov. 2020 Jul 20;10(8):1103–1120. doi: 10.1158/2159-8290.CD-19-1220

Figure 6.

Figure 6.

Survival analysis of individuals with sporadic mesothelioma or familial mesothelioma by BAP1 mutation status. Kaplan–Meier survival probability versus years with number at risk. Survival data combine results from references: (54, 67, 99). Blue, familial BAP1WT mesothelioma (median survival, 8 years; 10-year survival, 42.0%); red: familial BAP1+/− mesothelioma (median survival, 5 years; 10-year survival, 14.1%); green: SEER, stage I (median survival, 11 months; 10-year survival, 9.2%); brown: SEER, all stages (median survival, 8 months; 10-year survival, 3.3%). Rows below the graph indicate the number of patients at risk in each cohort per year. BAP1+/−, heterozygous BAP1-inactivating mutations; BAP1WT, wild-type BAP1; MM, malignant mesothelioma.